[Atypical antipsychotics and metabolic syndrome].
The introduction of atypical antipsychotics in psychopharmacology represented a major advance in the treatment of psychotic disorders. However, there have been numerous studies that certain atypical antipsychotics may be associated with a greater risk of metabolic abnormalities than others, including weight gain, hyperlipidemia and new-onset typ 2 diabetes mellitus. A G-Protein beta3 subunit Gen (C825T) polymorphism, an increased carbohydrate metabolism and dyshormonism are discussed as pathogenetic mechanisms. High risk patients (adiposity, hyperlipidaemia, hyperglycaemia, preexisting diabetes) should maintain an antipsychotic agent with a favourable side effect profile. In these cases a periodical diabetes screening and blood lipid controls are required. Clinicans must balance the significant benefits of atypical antipsychotics against the risk of metabolic disturbances. In this article recent findings are reviewed.
Baranyi
Andreas
A
Universitätsklinik für Psychiatrie Graz, Medizinische Universität Graz, Graz, Osterreich. Andreas.Baranyi@klinikum-graz.at
Yazdani
Renè
R
Haas-Krammer
Alexandra
A
Stepan
Alexandra
A
Kapfhammer
Hans-Peter
HP
Rothenhäusler
Hans-Bernd
HB
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015992:Body Mass Index; D050260:Carbohydrate Metabolism; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology*; D007333:Insulin Resistance; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000453:epidemiology*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012307:Risk Factors; D013997:Time Factors; D015430:Weight Gain
D014150:Antipsychotic Agents